Adherence therapy for people with schizophrenia in Suanprung Psychiatric Hospital, Thailand: a randomised controlled trial

Submission date	Recruitment status No longer recruiting	Prospectively registered	
24/10/2005		☐ Protocol	
Registration date	Overall study status Completed	Statistical analysis plan	
26/04/2006		[X] Results	
Last Edited	Condition category	Individual participant data	
20/01/2020	Mental and Behavioural Disorders		

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Richard Gray

Contact details

P O Box 30 De Crespigny Park Denmark Hill London United Kingdom SE5 8AF +44 (0)207 848 0139 r.gray@iop.kcl.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Study information

Scientific Title

Adherence therapy for people with schizophrenia in Suanprung Psychiatric Hospital, Thailand: a randomised controlled trial

Study objectives

Adherence therapy can reduce symptoms, increase attitude and satisfaction towards medication treatment

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Schizophrenia

Interventions

Treatment group: adherence therapy Control group: treatment as usual such as medication treatment, group counselling, occupational and recreational therapy

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Symptoms of schizophrenia measured using the positive and negative syndrome scale

Key secondary outcome(s))

- 1. Symptoms of schizophrenia measured using the Global Assessment of Functioning Scale
- 2. Attitude towards medication measured using the Hogan Drug Attitude Inventory
- 3. Satisfaction with medication measured using the Satisfaction With Antipsychotic Medication

Scale

4. Side effects of medication measured using the Liverpool University Neuroleptic Side Effect Rating Scale

Completion date

31/08/2005

Eligibility

Key inclusion criteria

- 1. Patients diagnosed by a psychiatrist with schizophrenia according to ICD-10 criteria (World Health Organisation ([WHO], 1992)
- 2. People with schizophrenia who are older than 20 years of age because they have reached the age of maturity legally and can provide consent independently
- 3. People with schizophrenia who have been assessed by a psychiatrist not involved in this study to determine that they can provide informed consent
- 4. People with schizophrenia who are residing in Muang Chiang Mai district

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

ΔII

Total final enrolment

32

Kev exclusion criteria

Patients suffering from organic brain diseases or learning disability

Date of first enrolment

01/12/2004

Date of final enrolment

31/08/2005

Locations

Countries of recruitment

United Kingdom

England

Thailand

Study participating centre P O Box 30 London United Kingdom SE5 8AF

Sponsor information

Organisation

The Royal Thai Government

ROR

https://ror.org/05fp08r12

Funder(s)

Funder type

Government

Funder Name

Praboromarajanok Institute of Workforce Development (Thailand)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/07/2007	31/05/2019	Yes	No